Kowa Of Japan Buys Control Of ProEthic Of U.S.
This article was originally published in PharmAsia News
Executive Summary
Japan's Kowa now owns 77.9 percent of ProEthic Pharmaceuticals of the United States, the Japanese firm announced. The purchase, valued at as much as $91.3 million, gives Kowa access to a sales network for its Livalo (pitavastatin) drug for treating hyperlipidemia, which the firm expects to launch in the United States in 2010. The U.S. company is to be renamed Kowa Pharmaceuticals America as of Sept. 1. Kowa plans to increase the ProEthic sales force beyond its current 65 people, in part to handle its drug for reducing triglyceride levels. (Click here for more - a subscription may be required